User login
Key clinical point: Chemoendocrine therapy vs endocrine-only therapy conferred longer invasive disease-free survival (iDFS) in premenopausal women with node-positive (node+) breast cancer (BC) and a recurrence score (RS) of ≤25 on a 21-gene assay.
Major finding: The 5-year iDFS was 93.9% in chemoendocrine group vs 89% in endocrine-only group with a significant chemotherapy benefit in premenopausal women (hazard ratio, 0.60; P = .002).
Study details: Findings are from RxPONDER, a prospective, ongoing phase 3 study, including 5,083 women with hormone receptor-positive/human epidermal growth factor receptor 2-negative BC, positive axillary lymph nodes, and RS of ≤25 who were randomly assigned to endocrine-only therapy or chemoendocrine therapy.
Disclosures: This study was supported by the National Cancer Institute, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health. The authors declared serving as a consultant, advisory board member, investigator and/or receiving grants and travel allowance from several sources.
Source: Kalinsky K et al. New Eng J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2108873.
Key clinical point: Chemoendocrine therapy vs endocrine-only therapy conferred longer invasive disease-free survival (iDFS) in premenopausal women with node-positive (node+) breast cancer (BC) and a recurrence score (RS) of ≤25 on a 21-gene assay.
Major finding: The 5-year iDFS was 93.9% in chemoendocrine group vs 89% in endocrine-only group with a significant chemotherapy benefit in premenopausal women (hazard ratio, 0.60; P = .002).
Study details: Findings are from RxPONDER, a prospective, ongoing phase 3 study, including 5,083 women with hormone receptor-positive/human epidermal growth factor receptor 2-negative BC, positive axillary lymph nodes, and RS of ≤25 who were randomly assigned to endocrine-only therapy or chemoendocrine therapy.
Disclosures: This study was supported by the National Cancer Institute, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health. The authors declared serving as a consultant, advisory board member, investigator and/or receiving grants and travel allowance from several sources.
Source: Kalinsky K et al. New Eng J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2108873.
Key clinical point: Chemoendocrine therapy vs endocrine-only therapy conferred longer invasive disease-free survival (iDFS) in premenopausal women with node-positive (node+) breast cancer (BC) and a recurrence score (RS) of ≤25 on a 21-gene assay.
Major finding: The 5-year iDFS was 93.9% in chemoendocrine group vs 89% in endocrine-only group with a significant chemotherapy benefit in premenopausal women (hazard ratio, 0.60; P = .002).
Study details: Findings are from RxPONDER, a prospective, ongoing phase 3 study, including 5,083 women with hormone receptor-positive/human epidermal growth factor receptor 2-negative BC, positive axillary lymph nodes, and RS of ≤25 who were randomly assigned to endocrine-only therapy or chemoendocrine therapy.
Disclosures: This study was supported by the National Cancer Institute, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health. The authors declared serving as a consultant, advisory board member, investigator and/or receiving grants and travel allowance from several sources.
Source: Kalinsky K et al. New Eng J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2108873.